Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3fg0XiD
via IFTTT